Skip to main content

Table 1 Clinical and demographic characteristics at baseline in AR patients

From: Higher efficacy of rupatadine 20 mg and 10 mg versus placebo in patients with perennial allergic rhinitis: a pooled responder analysis

 Placebo (N = 585)Rup 10 mg (N = 682)Rup 20 mg (N = 219)
Age (years), mean (SD)30.5 (12.1)30.6 (12.4)34.9 (13.4)
Sex (women), n (%)351 (60)415 (60.9)127 (58)
Weight (Kg), mean (SD)67.1 (14.1)67.3 (14.3)69.5 (14.3)
Height (cm), mean (SD)167.3 (9.6)166.6 (9.3)168.8 (9.5)
T4NSS (0–12), mean (SD)7.2 (2.0)7.2 (2.0)7.0 (1.6)
T5SS (0–15), mean (SD)8.4 (2.6)8.4 (2.5)8.0 (1.9)
  1. AR allergic rhinitis, Rup rupatadine, T4NSS Total 4 Nasal Symptom Score, T5SS Total 5 Symptom Score, SD standard deviation